Mounjaro®
Starting from £179.99/mo
Start journey Learn moreCurrent NHS guidance recommends stopping Mounjaro (tirzepatide) before any surgical procedure. NHS England advises telling your anaesthetist and the whole surgical team that you take a GLP-1 or dual-agonist medicine — and stopping treatment in advance — because slowed gastric emptying increases the risk of regurgitation and aspiration under anaesthesia. The exact timing should be confirmed by your surgical team, but the standard recommendation cited in NHS guidance is to stop at least one week before an elective procedure. This page sets out what is currently known, where the evidence is still developing, and who needs to make this call for your specific situation. Mounjaro is a prescription-only medicine; any decision about pausing, stopping or restarting it must involve your prescriber or surgical team, not a pharmacine read on your own.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide works partly by slowing how quickly food leaves the stomach. Under normal circumstances, a standard pre-operative fast of six hours for food and two hours for clear fluids reliably empties the stomach before a general anaesthetic. The concern with GLP-1 and dual GIP/GLP-1 medicines like Mounjaro is that this assumption may not hold: the medicine can keep stomach contents in place longer than expected, even when a patient believes they have fasted correctly.
The consequence of that mismatch is aspiration, inhaling stomach contents into the lungs during intubation or emergence from anaesthesia. This is a well-recognised anaesthetic risk and a serious one. NHS England's guidance on weight-management injections flags it directly, advising patients to tell their healthcare team, including the anaesthetist, before any surgical procedure. The NHS England weight-management injections page is the primary UK reference for this recommendation.
One detail worth noting: the risk is not simply a function of when you last ate. Because tirzepatide's mechanism persists across the week between injections, the residual pharmacological effect on gastric motility can linger even if your stomach feels subjectively empty. That is why the guidance extends beyond fasting advice and into stopping the medicine altogether before elective work.
The interval most commonly referenced in NHS and anaesthetic guidance for GLP-1 medicines is stopping at least one week before an elective procedure, effectively skipping one weekly dose of Mounjaro. This is consistent with the medicine's once-weekly dosing schedule and provides a reasonable washout period for the gastric-emptying effect to diminish, though it does not mean the medicine is fully cleared from the body within seven days.
For a fuller picture of timing considerations across different situations, the how long to stop Mounjaro before surgery page covers the range of scenarios in more depth. What is less settled is what to do before emergency procedures, before procedures under regional rather than general anaesthesia, or in patients at higher surgical risk for other reasons. The honest answer is that the evidence base here is still developing. Societies representing anaesthetists in the UK and internationally have published their own interim guidance, which your surgical team will be working from, and it may differ in detail from a general NHS patient information page.
If you are uncertain, the right step is to contact your surgical team directly and name the medicine and your current dose. Do not assume the pre-operative questionnaire covered it. A question our prescribers hear regularly is whether patients should just quietly pause and say nothing; they should not, the anaesthetic plan may need to change, and your team needs to know.
Pausing a weight-loss medicine before surgery is only half the picture. When to restart matters too, and it is genuinely individual. After abdominal surgery, gastrointestinal function may take time to normalise; reintroducing a medicine that further slows gastric emptying before the gut has recovered could worsen nausea, vomiting or ileus. For procedures with no GI involvement the calculus is different again.
There is no fixed number of days after which restart is automatically appropriate. Your prescriber and surgical team decide based on the type of procedure, your recovery trajectory and any complications. If you are a nume patient and your surgery is planned, the right time to flag it is before you stop, raise it during a consultation or via aftercare, so your prescriber can note it and help coordinate the restart plan. You can reach the team through our contact page any day of the week.
For broader context on how long people typically continue Mounjaro as a treatment and what happens when they pause, the how long you should use Mounjaro page sets out the general picture. And if this situation has you thinking about how the medicine works over time, how long Mounjaro takes to work covers the week-by-week trajectory in clinical terms.
If a procedure is already scheduled, work backwards from the date: contact your surgical team to confirm their required interval, then tell your Mounjaro prescriber so they can document the pause and avoid a repeat dispatch landing while you are mid-stop. Do not simply skip doses without telling anyone, a gap in treatment combined with a significant change in circumstances is exactly the kind of thing a prescriber needs to know about.
We know it can feel unsettling to pause treatment when things are going well. That frustration is entirely reasonable. If surgery has prompted you to reconsider your treatment plan more broadly, it is worth reading about when you should stop taking Mounjaro, which covers the clinical reasons a prescriber might recommend ending treatment, not just pausing it. The pause is temporary; the clinical review around restarting protects the continuity of your progress.
Mounjaro is licensed in the UK for weight management in adults with a qualifying BMI, and the Mounjaro overview page covers the full picture of how it works, eligibility and what private treatment involves. If you are not yet on treatment and are considering it ahead of (or after) a planned procedure, starting a free consultation is the first step; a GPhC-registered prescriber reviews your answers the same day and can take your surgical timeline into account, including questions about how long you should take Mounjaro given your circumstances, from the outset.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.